Notoriously hard to treat, pancreatic and colorectal cancers each have high recurrence rates in the years following treatment ...

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

Elicio's mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key ...

Scripps News speaks with vaccine experts who say HHS funding cuts targeting mRNA vaccines could hinder other vaccine research ...

In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back ...

Federal funding cuts to mRNA technology research doesn't just impact COVID vaccines — experts say it could stall progress in treatment for cancers, rare disease and more.

New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.

IO Biotech said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's ...

The "off-the-shelf" vaccine has also shown promising results for pancreatic cancer. Since the U.S. Preventive Services Task ...

A one-size-fits-all vaccine has shown promising results in keeping hard-to-treat pancreatic cancers from coming back. The ...